Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.38 |
| ▸ | NPY1R | P25929 | 3/20 | 0.38 |
| ▸ | NPY4R | P50391 | 3/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | CCKAR | P32238 | 1/20 | 0.37 |
| ▸ | CALCR | P30988 | 3/20 | 0.37 |
| ▸ | GRPR | P30550 | 1/20 | 0.37 |
| ▸ | CCKBR | P32239 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16358940 | 0.98 | ACE (0.38) | ACECRHR1CRHR2CALCRGRPR | |
| SCHEMBL16358941 | 0.91 | ACE (0.46) | ACENPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL16359347 | 0.91 | ACE (0.46) | ACENPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL16507899 | 0.86 | PTPN1 (0.44) | ACENPY4R | |
| SCHEMBL16507850 | 0.85 | NPY4R (0.47) | ACENPY4RCRHR1CRHR2 | |
| SCHEMBL31020877 | 0.81 | ACE (0.47) | ACENPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL16507827 | 0.81 | ACE (0.49) | ACENPY4R | |
| SCHEMBL16508075 | 0.80 | NPY4R (0.53) | NPY5RNPY1RNPY4RNPY2R | |
| SCHEMBL13363654 | 0.80 | ACE (0.49) | ACENPY4R | |
| SCHEMBL16508123 | 0.77 | REN (0.38) | GRPRCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | ANTHOR THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | PTH1R, MC1R, CASR | ACE 3206/4885NPY5R 1478/4885NPY1R 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.